Compare PRU & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRU | RMD |
|---|---|---|
| Founded | 1875 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | PRU | RMD |
|---|---|---|
| Price | $111.00 | $255.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $120.78 | ★ $292.20 |
| AVG Volume (30 Days) | ★ 1.8M | 1.0M |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | ★ 4.86% | 0.93% |
| EPS Growth | N/A | ★ 19.37 |
| EPS | 7.27 | ★ 10.11 |
| Revenue | ★ $57,598,000,000.00 | $5,398,119,000.00 |
| Revenue This Year | N/A | $9.88 |
| Revenue Next Year | $1.09 | $7.37 |
| P/E Ratio | ★ $15.28 | $25.55 |
| Revenue Growth | N/A | ★ 9.57 |
| 52 Week Low | $90.38 | $199.92 |
| 52 Week High | $123.41 | $293.81 |
| Indicator | PRU | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 56.08 |
| Support Level | $106.63 | $254.44 |
| Resistance Level | $109.44 | $261.00 |
| Average True Range (ATR) | 2.12 | 6.73 |
| MACD | -0.56 | 0.19 |
| Stochastic Oscillator | 32.90 | 64.67 |
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2024 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 40% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 10% of its 2024 adjusted earnings. PGIM had around $1.4 trillion in assets under management at the end of third-quarter 2025.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.